Teva 3Q Revenues:  $5.0 billion (+14%) 3Q Loss:  $79.0 million (earnings were $916 million 3Q11) YTD Revenues: $15.1 billion (+20%) YTD Earnings: $1.6 billion (-27%) Comments: Generic revenues in the quarter were $2.5 billion (including API sales of $195 million), up 1%. Branded revenues in the quarter were $2.0 billion, up 38%, primarily due to the inclusion of Cephalon’s medicines (mainly Treanda with $160 million, Nuvigil with $94 million and Provigil with $53 million). Also, Copa...